Documents - 2019

Displaying 1 - 20 of 26 results
 
Collapse Filters
 
Expand Filters         +
November 15, 2019

The Drug Situation in the Chicago Division (DIR-004-20)

The vast majority of drugs entering Chicago and the surrounding area, including fentanyl and fentanyl-related substances (FRS), heroin, cocaine, and methamphetamine, continue to be smuggled across the United States–Mexico border. Availability and abuse of these drugs is high, with opioids being the most prevalent in major cities and methamphetamine in rural areas. The primary organizational threats within the CFD are Mexican drug trafficking organizations (DTOs)—often referred to as cartels— that distribute illicit drugs through trusted intermediaries to local street gangs for retail sale.

November 15, 2019

Laboratory Operations Manual

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of November 15, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

October 28, 2019

Fentanyl Signature Profiling Program Report

The Fentanyl Signature Profiling Program (FSPP) performs in-depth chemical analyses on fentanyl and fentanyl-related exhibits obtained from seizures made throughout the United States.  This report details the results and conclusions derived from these analyses that are reported on a quarterly basis. FSPP data is not intended to reflect U.S. market share, but is rather a snapshot of samples submitted to this laboratory from the 7 DEA regional laboratories.

October 25, 2019

Prevenir El Uso De Marihuana Entre Adolescentes Y Adultos Jóvenes

Prevenir El Uso De Marihuana Entre Adolescentes Y Adultos Jóvenes (Preventing Marijuana use in Youth and Young Adults) 

October 23, 2019

Analysis of Drugs Manual

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of October 23, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

October 18, 2019

Fentanyl in Chicago – By the Numbers

The Drug Enforcement Administration (DEA) Chicago Field Division (CFD) conducted a study of all exhibits containing fentanyl and/or fentanyl-related substances (FRS) acquired within the CFD’s area of responsibility (AOR) between fiscal year (FY) 2015 and FY 2019 up to May 30, 2019. The CFD AOR includes the States of Illinois, Indiana, and Wisconsin. The exhibits included those acquired by DEA and other federal agencies, such as the Bureau of Alcohol, Tobacco, Firearms and Explosives and the Federal Bureau of Investigation.

October 11, 2019

Vaping and Marijuana Concentrates: What is Vaping?

Vaping is the act of inhaling and exhaling an aerosol or vapor made from a liquid or dry material that is heated in an electronic powered device, called an electronic cigarette, or e-cigarette.  In addition to nicotine and flavored liquids, marijuana concentrates can also be vaped. This 6-panel, double-sided trifold brochure covers the effects of using e-cigarettes, as well as the effects of marijuana concentrate

September 19, 2019

Drug Caused Deaths in the LA Field Division

The phenomenon of drug overdose death has grown steadily worse in the United States during most of the 21st century and has been skyrocketing since 2013 and the introduction of illicitly manufactured fentanyl-related substances into the domestic drug market...

September 16, 2019

Drug-Related Overdose Deaths in Pennsylvania, 2018 (BUL-132-19)

Since 2014, the Drug Enforcement Administration (DEA) Philadelphia Division Intelligence Program (PDIP) has annually collected and analyzed data and disseminated perceived trends and key findings that concern drug-related overdose deaths in Pennsylvania. This analysis has informed a multi-disciplinary audience relating to the drugs, populations, and geographic areas of greatest concern...

July 16, 2019

Statement Before House of Representatives Subcommittee on "Oversight of Federal Efforts to Combat the Spread of Illicit Fentanyl"

Statement of Matthew Donahue before the House of Representatives, Energy and Commerce Committee, Subcommittee on Oversight and Investigations for a hearing entitled, Oversight of Federal Efforts to Combat the Spread of Illicit Fentanyl.

June 4, 2019

Greg Cherundolo The Countdown: Fentanyl Analogues and the Expiring Emergency Scheduling Order

Greg Cherundolo Chief of Operations Office of Global Enforcement Drug Enforcement Administration U.S. Department of Justice before the United States Senate Judiciary Committee for hearing entitled:  The Countdown: Fentanyl Analogues and the Expiring Emergency Scheduling Order.

May 31, 2019

Updating the Prescription Opioid Threat in Pennsylvania

The Drug Enforcement Administration (DEA) Philadelphia Division’s Intelligence Program (PDIP) reviewed a set of data indicators for the years 2015-2018 to assess the current prescription opioid threat in Pennsylvania. Analysis revealed that a positive change in the prescription opioid threat may be underway...

April 25, 2019

SFL8 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Southwest Laboratory (SFL8).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL7 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Western Laboratory (SFL7).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL6 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the South Central Laboratory (SFL6).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL5 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the North Central Laboratory (SFL5).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL4 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Southeast Laboratory (SFL4).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL3 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Mid-Atlantic Laboratory (SFL3).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL2 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Northeast Laboratory (SFL2).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

 

DEA US Badge
United States Drug Enforcement Administration DEA.gov is an official site of the U.S. Department of Justice